ADA Annual Conference

Jul 09, 2025

STEP UP: A Powerful Leap Forward for WEGOVY (semaglutide) in the Obesity Market

Jul 09, 2025

Orforglipron at American Diabetes Association (ADA): Pioneering the Next Generation of Oral, Nonpeptide GLP-1 Therapies

Jul 09, 2025

Durable Glycemic Control and Elimination of Exogenous Insulin Use with Zimislecel (VX-880) in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD)

Jul 09, 2025

Once-monthly MariTide for the Treatment of Obesity in People with or without T2D: A 52-Week Phase II Study

Jul 09, 2025

MET-097i: A Fully Biased Ultra-long Acting GLP-1 Receptor Agonist

Jul 09, 2025

Eloralintide: A Promising Amylin Analog Positioned for the Next Wave of Obesity Therapies

Jul 09, 2025

CagriSema Shows Strong Dual-Hormone Promise in Obesity and T2D: Key Findings from REDEFINE Trials

Jul 09, 2025

Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With T1D: Insights From the FOURIER Trial

Jul 09, 2025

siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile

Newsletter/Whitepaper